ArticleFrontiers in neurology2021

A Phase II Study to Evaluate the Safety and Efficacy of Prasinezumab in Early Parkinson's Disease (PASADENA): Rationale, Design, and Baseline Data.

Gennaro Pagano et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.